Neoadjuvant Reirradiation for Radiation Therapy-Associated Angiosarcoma of the Breast
International Journal of Radiation Oncology*Biology*Physics · 2024-07 · 119 (4) · 1082-1085
DOI: 10.1016/j.ijrobp.2023.12.050 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2024-07. Verfasst von Wafa Asha und 10 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Radiation Oncology, Taussig Cancer Institute. Hauptthemen laut MEDLINE: Hemangiosarcoma, Breast Neoplasms, Re-Irradiation, Neoadjuvant Therapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Radiation-associated angiosarcoma of the breast (RAASB) is a rare side effect after breast radiation and has been associated with poor outcomes. At this time, there is no consensus regarding management of RAASB, and the role of reirradiation remains controversial. We present our modern institutional outcomes in managing RAASB with incorporation of neoadjuvant hyperfractionated reirradiation. METHODS AND MATERIALS: Patients identified were treated between 2016 and 2020 with inclusion of any histologically proven RAASB without metastatic disease at diagnosis, while excluding those with a history of radiation therapy outside of the breast/chest wall or other sarcoma histologies. Major wound complications were defined as requiring wound care and/or wound vacuum or return to the operating room for wound repair at any time after surgery. RESULTS: Eight patients were identified, and the median follow-up was 34 months. Median time to RAASB development was 8 years from initial radiation therapy. With respect to RAASB management, all underwent surgery and neoadjuvant reirradiation therapy, and all but 1 patient received taxol-based chemotherapy. At last follow-up, 7 patients remained free of disease, and 1 patient died with distant disease. With respect to acute toxicity after reirradiation, all patients developed at least acute grade 2 toxicities. Five of the 8 patients developed a major wound complication. CONCLUSIONS: Our institutional analysis suggests excellent local control and survival outcomes for RAASB treated with neoadjuvant hyperfractionated reirradiation, surgery, and taxol-based chemotherapy. However, major wound complications represent a major challenge with this approach. Future studies should consider how best to improve the therapeutic ratio while maintaining high rates of local control and survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Departments of Radiation Oncology, Taussig Cancer Institute.
- General Surgery, Digestive Diseases and Surgery Institute.
- Plastic Surgery, Digestive Diseases and Surgery Institute.
- Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
- Oncology Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates.
- Departments of Radiation Oncology, Taussig Cancer Institute. Electronic address: shahc4@ccf.org.
Zitieren
APA
Asha, W., Al-Hilli, Z., Djohan, R., Budd, G. T., Obi, E., Fleming-Hall, E., Yang, K., Grobmyer, S., Cherian, S., Tendulkar, R., & Shah, C. (2024). Neoadjuvant Reirradiation for Radiation Therapy-Associated Angiosarcoma of the Breast. International Journal of Radiation Oncology*Biology*Physics, 119(4), 1082-1085. https://doi.org/10.1016/j.ijrobp.2023.12.050
Vancouver
Asha W, Al-Hilli Z, Djohan R, Budd GT, Obi E, Fleming-Hall E, et al. Neoadjuvant Reirradiation for Radiation Therapy-Associated Angiosarcoma of the Breast. International Journal of Radiation Oncology*Biology*Physics. 2024;119(4):1082-1085. doi:10.1016/j.ijrobp.2023.12.050
BibTeX
@article{Asha2024,
author = {Asha, Wafa and Al-Hilli, Zahraa and Djohan, Risal and Budd, G Thomas and Obi, Elizabeth and Fleming-Hall, Erica and Yang, Kailin and Grobmyer, Stephen and Cherian, Sheen and Tendulkar, Rahul and Shah, Chirag},
title = {Neoadjuvant Reirradiation for Radiation Therapy-Associated Angiosarcoma of the Breast},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2024},
volume = {119},
number = {4},
pages = {1082--1085},
doi = {10.1016/j.ijrobp.2023.12.050}
}
EUVIMED